Outcome MeasureDepression

BPRS (Anxiety/Depression)

Brief Psychiatric Rating Scale – Anxious-Depression Subscale

2 Papers in Blossom

Clinical Thresholds

Minimal symptoms

Mild

Moderate

Severe

428

Minimal symptoms

Score 4–8

Mild

Score 9–14

Moderate

Score 15–21

Severe

Score 22–28

Outcome Data Across Studies

Reported results for BPRS (Anxiety/Depression) across 2 studies with quantitative data.

Outcome data across 3 study arm–timepoint observations
					SD
Investigation of medical effect of multiple ketamine infusions on patients with major depressive disorder 2019Secondary	Six ketamine infusions(experimental)	0	77	4.3	1.1	—
Investigation of medical effect of multiple ketamine infusions on patients with major depressive disorder 2019Secondary	Six ketamine infusions(experimental)	0.167	77	4.2	0.7	—
Prolonged ketamine infusion modulates limbic connectivity and induces sustained remission of treatment-resistant depression 2021Secondary	100-hour ketamine(experimental)	3	—	6.3	1.6	—

Papers Using BPRS (Anxiety/Depression)

Open Accessindividual

Prolonged ketamine infusion modulates limbic connectivity and induces sustained remission of treatment-resistant depression

This open-label study (n=23) found that a long (96 hours (4 days)) infusion of ketamine (10mg/70kg/h up to 42mg/70kg/h) significantly improved depressive symptoms (MADRS) for those suffering from treatment-resistant depression. This effect held up to two weeks later and the study also reported on the associated neurobiological changes.

Published: January 22, 2021
Journal: Psychopharmacology
Authors: Siegel, J. S., Palanca, B. J. A., Ances, B. M., Kharasch, E. D., Schweiger, J. A., Yingling, M. D., Snyder, A. Z., Nicol, G. E., Lenze, E. J., Farber, N. B.

Paywallindividual

Investigation of medical effect of multiple ketamine infusions on patients with major depressive disorder

This open-label study (n=77) examines the sustained effects of six consecutive ketamine infusions (0.5mg/kg over 40 min) in Chinese patients with major depressive disorder (MDD). Six ketamine infusions increased rates of response and remission when compared to a single-dose ketamine infusion in patients with MDD.

Published: February 21, 2019
Journal: Journal of Psychopharmacology
Authors: Zheng, W., Zhou, Y-L., Wang, C-Y.

Quick Facts

Full Name: Brief Psychiatric Rating Scale – Anxious-Depression Subscale
Domain: Depression
Papers Indexed: 2
Score Range: 4–28
Interpretation: Lower = better
Unit: points

All Measures